Printer Friendly

GENSIA RETAINS EXCLUSIVE MARKETING RIGHTS TO ARASINE

 SAN DIEGO, July 20 /PRNewswire/ -- Gensia Inc. (NASDAQ: GNSA) today announced that after discussions with its corporate partner Marion Merrell Dow Inc. (MMDI), it will retain exclusive marketing rights to Arasine. Marketing applications for Arasine have been submitted to regulatory authorities in the United States, Western Europe and Canada for use in coronary artery bypass graft surgery (CABG). According to David F. Hale, chairman, president and chief executive officer, "Due to the concentration of hospitals that perform CABG surgery and the relatively small number of physicians in our target physician audience (cardiothoracic surgeons and cardiac anesthesiologists), it has been our strategy to market Arasine directly if approved by the regulatory authorities, through a small Gensia sales force that will be highly specialized and very well trained. We believe that this strategy will maximize long-term value for our shareholders."
 Gensia entered into a Technology Option and License Agreement (the agreement) with MMDI in 1990, to develop orally active adenosine regulating agents (ARAs) for cardiovascular and cerebrovascular disease. MMDI has exclusive licensing rights to orally active ARAs developed under this agreement for cardiovascular and cerebrovascular disease, for North America, certain Europe and other countries. Marion licensed the first of these compounds, GP-1-468-3, in August 1992. As a part of the agreement, Gensia also granted MMDI a right to negotiate a co-promotion agreement for intravenously administered ARAs, including Arasine, for cardiovascular and cerebrovascular disease. While Gensia and MMDI have agreed that Gensia will retain exclusive market rights for Arasine, MMDI has indicated that it would be prepared to enter into discussions for a co-promotion agreement if Gensia should later decide that it wishes to have a co-promotion partner.
 Gensia Inc. is a San Diego-based bio-pharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human disease.
 -0- 7/20/93
 /CONTACT: Elizabeth A. Gard, director-corporate communications of Gensia, 619-546-8300/
 (GNSA)


CO: Gensia Inc.; Marion Merrell Dow Inc. ST: California IN: MTC SU:

BP-EH -- SD004 -- 6840 07/20/93 12:47 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1993
Words:336
Previous Article:/REPEATING FOR POINTS REQUESTING/
Next Article:PLUM CREEK TIMBER CO., L.P., ANNOUNCES A 93 PERCENT INCREASE IN SECOND QUARTER EARNINGS
Topics:


Related Articles
GENSIA LABORATORIES RECEIVES ANDA APPROVAL FOR SODIUM NITROPRUSSIDE
MARION MERRELL DOW EXERCISES RIGHT TO LICENSE GENSIA ARA COMPOUND
GENSIA ANNOUNCES ARASINE CLINICAL RESULTS AND PLANS FOR REGULATORY SUBMISSIONS
GENSIA TO PROCEED AS PLANNED WITH ARASINE REGULATORY FILINGS IN UNITED STATES AND EUROPE
GENSIA FILES NDA FOR ARASINE AS PLANNED WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
GENSIA FILES REGULATORY SUBMISSIONS FOR ARASINE AS PLANNED IN EUROPEAN MARKETS
GENSIA LABORATORIES RECEIVES ANDA APPROVALS FOR INJECTABLE ANTI-INFECTIVE AND ADJUNCT TO CHEMOTHERAPY
GENSIA OBTAINS EXCLUSIVE EUROPEAN MARKETING RIGHTS TO INNOVATIVE CARDIOVASCULAR DRUG FROM OHMEDA
Gensia Laboratories and Microbix Complete Licensing Agreement for Acute Cardiovascular Product
Gensia Sicor Announces Amended Manufacturing and Distribution Agreement With Baxter Pharmaceutical Products Inc.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters